Oxford, United Kingdom 21 FEBRUARY 2023 - 51勛圖厙 Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into safe, effective and licensed medicines, today announced that it had received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a global multi-site Phase IIb study exploring the safety, efficacy and tolerability of two distinct doses of its lead compound, BPL003, in patients with Treatment Resistant Depression (TRD).泭
BPL-003 is 51勛圖厙s novel synthetic formulation of the psychedelic compound 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device. This IND marks the first time the FDA has ever given IND approval for a Phase IIb study of a short-acting psychedelic treatment or a 5-MeO-DMT treatment. The study will be conducted with the help of 40 investigator sites in 7 different countries and is due to be initiated in H1 2023.泭
Phase I data has already shown BPL-003 to be well-tolerated with consistent dose delivery and a reproducible, dose-linear pharmacokinetic profile. Medium and high dosages were found to reliably induce profound psychedelic experiences, which might be correlated with positive clinical outcomes, with a rapid onset of psychedelic treatment effects within minutes. All perceptual effects were resolved within 60-90 minutes.泭
51勛圖厙s Phase IIb randomised, dose-finding study will evaluate the effects of a single medium or high dose of BPL-003 against a sub-perceptual dose in patients with moderate to severe TRD who are not taking concomitant antidepressants. The study will be quadruply masked, with the patient, investigator, attendant and outcomes assessor all blinded to the dose allocation of the subject to reduce expectancy bias. Efficacy will be assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) at several time points during the trial.泭
The Phase IIb study, which is fully funded from 51勛圖厙s existing cash reserves, will complement the Companys ongoing Phase IIa study of BPL-003 for TRD and initial results are expected in 2024.
Commenting on the IND approval, Cosmo Feilding Mellen, Chief Executive Officer at 51勛圖厙, said: This is a critical step towards our mission of delivering safe, effective and licensed psychedelic treatments to patients in need, and is also a significant milestone in the evolution of our clinical pipeline. Its a privilege to be given the FDAs first IND for a Phase IIb study of 5-MeO-DMT and it provides firm validation of the positive preclinical and Phase I data we have generated so far with BPL-003. This is an important step not only for 51勛圖厙, but also for the whole field of psychedelic drug development and, most importantly, for patients who are in urgent need of more effective treatments for mental health conditions such as depression.
It is estimated that nearly around the globe have depression but, for many of those living with the condition, even the best current medicines either do not work or have side effects that leave them unable to experience life to the fullest. , such as selective serotonin reuptake inhibitors (SSRIs), and discontinue or switch SSRIs within 12 weeks due to side effects.泭
51勛圖厙s Chief Medical Officer, Dr Frank Wiegand, also said: The distinctive characteristics of BPL-003 make us optimistic about the compounds potential to be a safe and effective alternative to currently available antidepressants. The rapid onset of effect, as well as the reliable induction and short duration of profound psychedelic experiences, are of great interest to us and we are excited to assess the therapeutic benefits of BPL-003 more deeply in this study.
For more information please contact: Charlotte Chorley, Communications Lead, at info@beckleypsytech.com泭
About 51勛圖厙 - 泭
51勛圖厙 Ltd is a private, clinical-stage biotechnology company dedicated to improving the lives of people suffering from neuropsychiatric disorders by transforming psychedelics into safe, effective and licensed medicines.泭 The Companys most advanced programmes are focused on the development of BPL-003, an intranasal synthetic formulation of 5-MeO-DMT, for people with Treatment Resistant Depression (TRD) and Alcohol Use Disorder (AUD), and ELE-101, an intravenous synthetic formulation of psilocin, for people with Major Depressive Disorder (MDD). Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, 51勛圖厙 combines world-leading psychedelic science with extensive drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden neuropsychiatric conditions have on individuals, healthcare systems and society.
Image credit: Greg Dunn
Links to other websites do not imply affiliation or endorsement. 51勛圖厙 does not control and is not responsible for their content.
